Abhijit Debnath

@nietpharmacy.co.in

Pharmaceutics
Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida



                                         

https://researchid.co/theabhijitdn

RESEARCH, TEACHING, or OTHER INTERESTS

Drug Discovery, Pharmacology, Toxicology and Pharmaceutics, Pharmacology, Pharmaceutical Science

20

Scopus Publications

51

Scholar Citations

4

Scholar h-index

1

Scholar i10-index

Scopus Publications


  • Experimental, quantum chemical spectroscopic investigation, topological, molecular docking/dynamics and biological assessment studies of 2,6-Dihydroxy-4-methyl quinoline
    Rakesh Chandra Joshi, Shahid Husain, Nupur Pandey, Nisha Fatma, Divya Bisen, Ratnakar Upadhyay, Abhijit Debnath, Sanjay Pant, and Hirdyesh Mishra
    Elsevier BV

  • Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
    Abhijit Debnath, Rupa Mazumder, Anil Kumar Singh, and Rajesh Kumar Singh
    Public Library of Science (PLoS)
    Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial regulators of cell cycle progression and represent important therapeutic targets in breast cancer. This study employs a comprehensive computational approach to identify novel CDK4/6 inhibitors from marine natural products. We utilized structure-based virtual screening of the CMNPD database and MNP library, followed by rigorous filtering based on drug-likeness criteria, PAINS filter, ADME properties, and toxicity profiles. From an initial hit of 9,497 compounds, 2,344 passed drug-likeness and PAINS filters. Further ADME filtering yielded 50 compounds, of which 25 exhibited non-toxic profiles. These 25 candidates underwent consensus molecular docking using seven distinct algorithms: AutoDockTools 4.2, idock, LeDock, Qvina 2, Smina, AutoDock Vina 1.2.0, PLANTS, and rDock. Based on these results, six top-scoring compounds were selected for comprehensive 500 nanosecond all-atom molecular dynamics simulations to evaluate their structural stability and interactions with CDK4/6. Our analysis revealed that compounds CMNPD11585 and CMNPD2744 demonstrated superior stability in their interactions with CDK4/6, exhibiting lower RMSD and RMSF values, more favorable binding free energies, and persistent hydrogen bonding patterns. These compounds also showed lower Solvent Accessible Surface Area values, indicating better compatibility with the CDK4/6 active site. Subsequent in-vitro studies using MTT assays on MCF-7 breast cancer cells confirmed the cytotoxic effects of these compounds, with CMNPD11585 showing the highest potency, followed by CMNPD2744.

  • Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites
    Abhijit Debnath, Rupa Mazumder, Rajesh Kumar Singh, and Anil Kumar Singh
    Elsevier BV

  • Role of PD-1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
    Neha Sharma, Rupa Mazumder, Pallavi Rai, and Abhijit Debnath
    Wiley
    ABSTRACTSkin cancer is a widespread worldwide health concern, manifesting in many subtypes such as squamous cell carcinoma, basal cell carcinoma, and melanoma. Although all these types occur frequently, they generally lack the possibility of being cured, emphasizing the importance of early discovery and treatment. This comprehensive study explores the role of programmed cell death protein 1 (PD‐1) in skin cancer, focusing on its molecular mechanisms in immune regulation and its critical role in tumor immune evasion, while also clarifying the complexities of immune checkpoints in cancer pathogenesis. It critically evaluates the clinical applications of PD‐1 inhibitors, spotlighting their therapeutic potential in treating skin cancer, while also addressing the significant challenge of resistance. This work further discusses the evolution of resistance mechanisms against PD‐1 inhibitors and suggests potential approaches to mitigate these issues, thereby enhancing the effectiveness of these therapies. The study further highlights the current state of PD‐1 targeted therapies and sets the stage for future research aimed at optimizing these treatments for better clinical outcomes in skin cancer.

  • Three-Dimensional Hydrogel Bioprinting Technology as a Scaffold of Novel Drug Delivery and Biomedical Devices: A Comprehensive Review
    Mohhammad Ramzan, Mohammed Sabir, Sukhbir Singh, and Abhijit Debnath
    EDP Sciences
    Polymer hydrogel used as computer-aided, non-biological arsenal utilize as a drug delivery vehicle overthe past few years.New advances in three-dimensional (3D) bioprinting technology have created new opportunitiesfor the use of hydrogel polymer-based medication delivery systems. 3D printing can deliver the ideal shapes or changecapabilities under specific circumstances which have a better adaptation to physiological function. The accuracy of 3Dprinting technology was significantly higher than that of conventional production techniques.A model bioink acquireproper physicochemical characteristics (mechanical and rheological) and biological properties important for proper functioning.It acts as additive manufacturing with complex spatial structure in biomedical research. In this review, we outlined the currentdevelopments in 3D printed polymer hydrogels as delivery and other platforms.

  • Quest for discovering novel CDK12 inhibitor
    Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Avijit Mazumder, Shikha Srivastava, Hema Chaudhary, Saloni Mangal, Jahanvi Sanchitra, Pankaj Kumar Tyagi, Sachin Kumar Singh,et al.
    Informa UK Limited
    CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Consequently, this research aims to identify effective CDK12 inhibitors using comprehensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, MD Simulation, and in-vitro studies MTT assay. The research conducted yielded one compound ZINC11784547 has demonstrated robust binding affinity, favorable ADME features, less toxicity, remarkable stability, and cytotoxic effect. The identified compound holds promise for promoting cancer cell death through CDK12 inhibition.

  • Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
    Saloni Mangal, Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Rajesh Kumar Singh, Jahanvi Sanchitra, S.K. Asif Jan, Pratibha Pandey, Bimlesh Kumar, and Anil Kumar Singh
    Informa UK Limited

  • A Deep Dive into PDE5 Inhibition: Innovative Discoveries via Virtual Screening
    Abhijit Debnath, Hema Chaudhary, Parul Sharma, Rajesh Singh, and Shikha Srivastava
    Bentham Science Publishers Ltd.
    Background: PDE5 inhibitors have had a surge in popularity over the last decade owing to their efficacy in the treatment of erectile dysfunction, coronary vasculopathy, and pulmonary arterial hypertension. These inhibitors exhibit competitive binding with phosphodiesterase type 5 and inhibit the hydrolysis of cyclic guanosine monophosphate, hence elevating the levels of cGMP in smooth muscle cells and prolonging the duration of an erection. However, due to production costs and side effects, further research is needed to discover new PDE5 inhibitors. background: The field of PDE5 inhibitors has risen in popularity in the past decade because of the success of PDE5 inhibitors in treating erectile dysfunction. Due to the structural identity with cGMP; PDE5 inhibitors competitively bind with PDE5 and limit cGMP hydrolysis, which raises the cGMP level in smooth muscle cells and lengthens the duration of an erection. PDE5 inhibitors were also found to be beneficial for coronary vasculopathy, pulmonary arterial hypertension, and benign prostatic hyperplasia. But, due to the expensive cost of production and unwanted side effects, it is necessary to explore the possibility of the discovery of new PDE5 inhibitors. Objective: The study aimed to identify potent PDE5 inhibitors by employing the extensive application of computer-aided drug design. objective: To identify potent PDE5 inhibitors by employing the extensive application of computer-aided drug design. Method: Three different databases, named Million Molecules Database, Natural Product Database, and NCI Database, have been screened, which has been followed by filtering based on various druglikeness rules, docking, ADME, toxicity, consensus molecular docking, and 100 ns molecular dynamics simulation. method: Three different databases named Million Molecules Database, Natural Product Database, and NCI Database has been screened followed by filtering based on various drug-likeness such as Lipinski rule of five, Ghose rule, Veber rule, and Muegge rule, docking, ADME, toxicity, consensus molecular docking, and 100 ns Molecular dynamics simulation Results: Three compounds (ZINC05351336, ZINC12030898, and ZINC17949426) have exhibited stable-binding characteristics at the active site of PDE5, demonstrating a robust binding affinity. These molecules have been found to possess drug-like capabilities, effective ADME features, low toxicity, and high stability. Conclusion: The study has delved into the realm of PDE5 inhibitors, which have been found to be effective in treating erectile dysfunction, but high production costs and side effects necessitate new ones. Through computer-aided drug design and screening, three compounds have been identified with promising binding characteristics, drug-appropriate properties, effective ADME profiles, minimal toxicity, and stability, making them potential candidates for future PDE5 inhibitors

  • Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening
    Abhijit Debnath and Rupa Mazumder
    Bentham Science Publishers Ltd.
    Background:: CDK4/6 plays a crucial role in regulating cell proliferation, and inhibiting this kinase can effectively prevent the initiation of cell growth and division. However, current FDAapproved CDK4/6 inhibitors have limitations such as poor bioavailability, adverse effects, high cost, and limited accessibility. Thus, this research aimed to discover novel CDK4/6 inhibitors to overcome the challenges associated with FDA-approved inhibitors. Methods:: To identify potential CDK4/6 inhibitors, we have performed structure-based virtual screening. Chem-space and Mcule databases have been screened, followed by a series of filtering steps. These steps included assessing drug-likeness, PAINS alert, synthetic accessibility scores, ADMET properties, consensus molecular docking, and performing molecular dynamics simulations. Results:: Four new compounds (CSC089414133, CSC091186116, CSC096023304, CSC101755872) have been identified as potential CDK4/6 inhibitors. These compounds exhibited strong binding affinity with CDK4/6, possessed drug-like features, showed no PAINS alert, had a low synthetic accessibility score, demonstrated effective ADMET properties, were non-toxic, and exhibited high stability. Conclusion:: Inhibiting CDK4/6 with the identified compounds may lead to reduced cell proliferation and the promotion of cancer cell death. result: Four compounds (CSC089414133, CSC091186116, CSC096023304, CSC101755872) were identified as potential CDK4/6 inhibitors. These compounds exhibited strong binding affinity at the active site of CDK4/6, possessed drug-like features, showed no PAINS alert, had a low synthetic accessibility score, demonstrated effective ADMET properties, were non-toxic, and exhibited high stability.

  • In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
    Abhijit Debnath, Shalini Sharma, Rupa Mazumder, Avijit Mazumder, Rajesh Singh, Ankit Kumar, Arpita Dua, Priya Singhal, Arvind Kumar, and Gurvinder Singh
    Bentham Science Publishers Ltd.
    Background: Type 2 diabetes mellitus constitutes approximately 90% of all reported forms of diabetes mellitus. Insulin resistance characterizes this manifestation of diabetes. The prevalence of this condition is commonly observed in patients aged 45 and above; however, there is an emerging pattern of younger cohorts receiving diagnoses primarily attributed to lifestyle-related variables, including obesity, sedentary behavior, and poor dietary choices. The enzyme SGLT2 exerts a negative regulatory effect on insulin signaling pathways, resulting in the development of insulin resistance and subsequent elevation of blood glucose levels. The maintenance of glucose homeostasis relies on the proper functioning of insulin signaling pathways, while disruptions in insulin signaling can contribute to the development of type 2 diabetes. Objective: Our study aimed to investigate the role of SGLT2. This enzyme interferes with insulin signaling pathways and identifies potential SGLT2 inhibitors as a treatment for managing type 2 diabetes. Methods: We screened the Maybridge HitDiscover database to identify potent hits followed by druglikeness, Synthetic Accessibility, PAINS alert, toxicity estimation, ADME assessment, and Consensus Molecular docking Results: The screening process led to the identification of three molecules that demonstrated significant binding affinity, favorable drug-like properties, effective ADME, and minimal toxicity. Conclusion: The identified molecules could manage T2DM effectively by inhibiting SGLT2, providing a promising avenue for future therapeutic strategies

  • In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics Simulation Study
    Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Rajesh Singh, and Shikha Srivastava
    Bentham Science Publishers Ltd.
    Background: Multiple myeloma (MM) is a hematological malignancy of plasma cells that produce a monoclonal immunoglobulin protein. Despite significant advances in the treatment of MM, currently available therapies are associated with toxicity and resistance. As a result, there is an increasing demand for novel, effective therapeutics. Inhibition of histone deacetylases (HDACs) is emerging as a potential method for treating cancer. HDAC6 is one of 18 different HDAC isoforms that regulate tubulin lysine 40 and function in the microtubule network. HDAC6 participates in tumorigenesis and metastasis through protein ubiquitination, tubulin, and Hsp90. Several studies have found that inhibiting HDAC6 causes AKT and ERK dephosphorylation, which leads to decreased cell proliferation and promotes cancer cell death via the PI3K/AKT and MAPK/ERK signaling pathways. Objective: The objective of this study is to target HDAC6 and identify potent inhibitors for the treatment of multiple myeloma by employing computer-aided drug design. Materials and Methods: A total of 199,611,439 molecules from five different chemical databases, such as CHEMBL25, ChemSpace, Mcule, MolPort, and ZINC, have been screened against HDAC6 by structure- based virtual screening, followed by filtering for various drug-likeness, ADME, toxicity, consensus molecular docking, and 100 ns MD simulation. Results: Our research work resulted in three molecules that have shown strong binding affinity (CHEMBL2425964 -9.99 kcal/mol, CHEMBL2425966 -9.89 kcal/mol, and CSC067477144 -9.86 kcal/mol) at the active site HDAC6, along with effective ADME properties, low toxicity, and high stability. Inhibiting HDAC6 with these identified molecules will induce AKT and ERK dephosphorylation linked to reduced cell proliferation and promote cancer cell death. Conclusion: CHEMBL2425964, CHEMBL2425966, and CSC067477144 could be effective against multiple myeloma.




  • A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
    Rupa Mazumder, Kamal Kant Kaushik, Abhijit Debnath, and Manisha Patel
    Bentham Science Publishers Ltd.
    Background: Even with the massive increase in financial investments in pharmaceutical research over the last decade, the number of new drugs approved has plummeted. As a result, finding new uses for approved pharmaceuticals has become a prominent alternative approach for the pharmaceutical industry. Objective: Drug repurposing or repositioning is a game-changing development in the field of drug research that entails discovering additional uses for previously approved drugs. Methods: In comparison to traditional drug discovery methods, drug repositioning enhances the preclinical steps of creating innovative medications by reducing the cost and time of the process. Drug repositioning depends heavily on available drug-disease data, so the fast development of available data as well as developed computing skills has resulted in the boosting of various new drug repositioning methods. The main goal of this article is to describe these different methods and approaches for drug repurposing. Results: The article describes the basic concept of drug repurposing, its significance in discovering new medications for various disorders, drug repurposing approaches such as computational and experimental approaches, and previous as well as recent applications of drug repurposing in diseases such as cancer, COVID-19, and orphan diseases. Conclusion: The review also addresses obstacles in drug development using drug repurposing strategies, such as a lack of financing and regulatory concerns and concludes with outlining recommendations for overcoming these challenges.

  • High-throughput virtual screening of novel CHK1 inhibitors


  • A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT
    MANISHA PATEL, RUPA MAZUMDER, KAMAL KANT KAUSHIK, ABHIJIT DEBNATH, RAKHI MISHRA, and SHUBHAM PAL
    Innovare Academic Sciences Pvt Ltd
    A novel coronavirus disease, which is transmitted from human to human has quickly become the cause of the current worldwide health crisis. This virus is, also known as SARS coronavirus, belongs to the Coronaviridae family of viruses. The recent outbreak of acute respiratory disorders starting in Wuhan, China is found to be caused by this virus. The condition caused by it, known as COVID-19 has spread very rapidly all over the world, causing so many death. This led WHO on Mar 11, 2020, to designate it as a global pandemic. An update on the history, etiology, epidemiology, pathophysiology and preventive methods for COVID-19 such as masking, quarantine, and social distancing are discussed in this paper. Repurposed drugs, antibodies, corticosteroids, vaccination and plasma transfusion, are among the treatments explained in the study. Finally, the study discusses India’s COVID vaccination programme. The major aspects of this entire review are to describe COVID-19 infection, its prevention and treatment approach.

  • IN-SILICO INVESTIGATION BASED PLANT SECONDARY METABOLITES AS PROMISING IMMUNOSTIMULANTS AGAINST COVID-19



RECENT SCHOLAR PUBLICATIONS

  • Integration of In-vivo screening, molecular docking, and molecular dynamics simulations for studying the antiepileptic potential of newly synthesized 5-naphthalen-1-yl-5, 10
    R Kumar, H Singh, A Debnath, A Mazumder, N Bano, V Khanna, ...
    Journal of Molecular Structure 1324, 140814 2025

  • Experimental, quantum chemical spectroscopic investigation, topological, molecular docking/dynamics and biological assessment studies of 2, 6-Dihydroxy-4-methyl quinoline
    RC Joshi, S Husain, N Pandey, N Fatma, D Bisen, R Upadhyay, ...
    Journal of Molecular Structure 1321, 140123 2025

  • Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
    A Debnath, R Mazumder, AK Singh, RK Singh
    Plos one 20 (1), e0313830 2025

  • Quest for discovering novel CDK12 inhibitor
    A Debnath, RK Singh, R Mazumder, A Mazumder, S Srivastava, ...
    Journal of Receptors and Signal Transduction 45 (1), 1-21 2025

  • Advancements of glucose monitoring biosensor: current state, generations of technological progress, and innovation dynamics
    A Dua, A Debnath, K Kumar, R Mazumder, A Mazumder, R Singh, ...
    Current Pharmaceutical Biotechnology 2025

  • Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
    S Mangal, A Debnath, R Mazumder, A Mazumder, RK Singh, J Sanchitra, ...
    All Life 17 (1), 2417192 2024

  • A Deep Dive into PDE5 Inhibition: Innovative Discoveries via Virtual Screening
    A Debnath, H Chaudhary, P Sharma, R Singh, S Srivastava
    Letters in Drug Design & Discovery 21 (16), 3425-3442 2024

  • Identification of novel CDK 4/6 inhibitors by high-throughput virtual screening
    A Debnath, R Mazumder
    Letters in Drug Design & Discovery 21 (15), 3229-3246 2024

  • Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites
    A Debnath, R Mazumder, RK Singh, AK Singh
    International Journal of Biological Macromolecules 282, 136807 2024

  • Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening
    A Debnath, A Rani, R Mazumder, A Mazumder, RK Singh, S Sharma, ...
    Current Computer-Aided Drug Design 2024

  • Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
    N Sharma, R Mazumder, P Rai, A Debnath
    Chemical Biology & Drug Design 104 (3), e14613 2024

  • In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
    A Debnath, S Sharma, R Mazumder, A Mazumder, R Singh, A Kumar, ...
    Current Drug Discovery Technologies 21 (3), 20-31 2024

  • Clinical progress of targeted therapy for breast cancer: A comprehensive review
    A Debnath, R Mazumder
    Curr Cancer Drug Targets 24, 9091 2024

  • In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and
    A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava
    Letters in Drug Design & Discovery 21 (5), 961-978 2024

  • Biological Potentials of Carbazole Derivatives: A Review
    AD Babita Kumari, Sucheta1, Arpana Rana, Sheo Mohan Singh
    African Journal of Biological Sciences 6 (5), 3288-3297 2024

  • miRNA-Targeted Vaccines: A Promising Approach for Viral Attenuation and Immunogenicity Enhancement
    A Debnath, R Mazumder, A Mazumder, S Tripathi, A Dua, R Singh, ...
    Current gene therapy 2024

  • Potential of Azadirachta indica A. Juss., Eucalyptus globulus Labill. and Ocimum sanctum L. Phytochemicals as Herbal Hand Sanitizer: A Review.
    P Jain, R Mishra, A Debnath, S Sharma
    Allelopathy Journal 60 (2) 2023

  • Quest for Discovering Novel CDK12 Inhibitor by Leveraging High-Throughput Virtual Screening
    A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava, ...
     2023

  • A brief study on drug repurposing: new way of boosting drug discovery
    KK Kaushik, R Mazumder, A Debnath, M Patel
    Letters in Drug Design & Discovery 20 (3), 264-278 2023

  • High-throughput virtual screening of novel CHK1 inhibitors.
    A Debnath, H Chaudhary, S Roy, S Srivastava
    Onkologia i Radioterapia 17 (1) 2023

MOST CITED SCHOLAR PUBLICATIONS

  • In silico Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and
    A Debnath, R Mazumder, A Mazumder, R Singh, S Srivastava
    Letters in Drug Design & Discovery 21 (5), 961-978 2024
    Citations: 12

  • A brief study on drug repurposing: new way of boosting drug discovery
    KK Kaushik, R Mazumder, A Debnath, M Patel
    Letters in Drug Design & Discovery 20 (3), 264-278 2023
    Citations: 7

  • Identification of novel CDK 4/6 inhibitors by high-throughput virtual screening
    A Debnath, R Mazumder
    Letters in Drug Design & Discovery 21 (15), 3229-3246 2024
    Citations: 4

  • A brief description of COVID-19 pulmonary viral infection and repurposing of drugs for its treatment
    M Patel, R Mazumder, KK Kaushik, A Debnath, R Mishra, S Pal
    PATEL M, MAZUMDER R, KAUSHIK KK, DEBNATH A, MISHRA R, PAL S. A BRIEF 2022
    Citations: 4

  • Advancements of glucose monitoring biosensor: current state, generations of technological progress, and innovation dynamics
    A Dua, A Debnath, K Kumar, R Mazumder, A Mazumder, R Singh, ...
    Current Pharmaceutical Biotechnology 2025
    Citations: 3

  • Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites
    A Debnath, R Mazumder, RK Singh, AK Singh
    International Journal of Biological Macromolecules 282, 136807 2024
    Citations: 3

  • Clinical progress of targeted therapy for breast cancer: A comprehensive review
    A Debnath, R Mazumder
    Curr Cancer Drug Targets 24, 9091 2024
    Citations: 3

  • Experimental, quantum chemical spectroscopic investigation, topological, molecular docking/dynamics and biological assessment studies of 2, 6-Dihydroxy-4-methyl quinoline
    RC Joshi, S Husain, N Pandey, N Fatma, D Bisen, R Upadhyay, ...
    Journal of Molecular Structure 1321, 140123 2025
    Citations: 2

  • A Deep Dive into PDE5 Inhibition: Innovative Discoveries via Virtual Screening
    A Debnath, H Chaudhary, P Sharma, R Singh, S Srivastava
    Letters in Drug Design & Discovery 21 (16), 3425-3442 2024
    Citations: 2

  • Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
    N Sharma, R Mazumder, P Rai, A Debnath
    Chemical Biology & Drug Design 104 (3), e14613 2024
    Citations: 2

  • Kidney targeting approaches In The Drug Delivery arena
    Singh S, Mazumder R, Debnath A, Dutta A
    NeuroQuantology 20 (8), 3424-3444 2022
    Citations: 2

  • PD 1: A Trending Target in Anti-cancer Research
    S Rani, R Mazumder, N Sharma, R Mishra, A Debnath, SD Paul
    Biointerface Research in Applied Chemistry 13 (3), 218 2022
    Citations: 2

  • Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
    S Mangal, A Debnath, R Mazumder, A Mazumder, RK Singh, J Sanchitra, ...
    All Life 17 (1), 2417192 2024
    Citations: 1

  • Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening
    A Debnath, A Rani, R Mazumder, A Mazumder, RK Singh, S Sharma, ...
    Current Computer-Aided Drug Design 2024
    Citations: 1

  • In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
    A Debnath, S Sharma, R Mazumder, A Mazumder, R Singh, A Kumar, ...
    Current Drug Discovery Technologies 21 (3), 20-31 2024
    Citations: 1

  • miRNA-Targeted Vaccines: A Promising Approach for Viral Attenuation and Immunogenicity Enhancement
    A Debnath, R Mazumder, A Mazumder, S Tripathi, A Dua, R Singh, ...
    Current gene therapy 2024
    Citations: 1

  • Discovery of Novel Cathepsin D Inhibitors by High-Throughput Virtual Screening
    A Debnath, H Chaudhary, R Kumar, A Shokeen, R Khurana
    neurodegenerative diseases 9, 10 2023
    Citations: 1